



Final payment received for the sale of IOptima Ltd to Chengdu Kanghong Pharmaceuticals Group, Co.

BioLight is proud to report that on June 24, 2021, BioLight received a total amount of approximately \$5.6 million constituting the fourth and final stage of the investment agreement and full acquisition of IOptima Ltd. ("IOptima") by the China based pharmaceuticals company Chengdu Kanghong Pharmaceutical Group Co. ("The Agreement", "The Pharmaceutical Company")

With the completion of the fourth and final stage of The agreement, The Pharmaceutical Company completed the acquisition of the remaining shares of IOptima and BioLight no longer has any holdings in IOptima nor the entitlement to a director on its behalf.

It should be noted that the aforementioned does not affect BioLight's right to receive royalties from IOptima by virtue of a sub-license agreement for the marketing and sale of LipiTear™, an approved medical product in the European Union for the treatment of Dry Eye Syndrome (DES)

About BioLight

BioLight Life Sciences Ltd. is a leading company investing in companies and managing projects relating to eye diseases and their treatment. BioLight's portfolio companies engage in advanced medical devices, medication, diagnostics and digital medicine and all exemplifying the enormous potential of innovation in the ophthalmological technologies.

The ophthalmic products developed by the companies in the BioLight group are aimed at innovative diagnosis and treatments for the needs of patient groups suffering from eye diseases. The different ophthalmic products are in various commercialization and clinical (or pre-clinical) phases.